Serotherapy in transplant: Getting it right!
British Journal of Haematology · 2026-05 · 208 (5) · 1885-1886
DOI: 10.1111/bjh.70456 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Haematology, online erschienen am 06.04.2026. Verfasst von Robert Wynn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital, Manchester, UK. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Alemtuzumab. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Commentary on: Madkhali et al. Dose de‐escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2026; 208:1477–1481.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital, Manchester, UK.
- Pediatric Blood and Marrow Transplantation Program, Princess Máxima Centre for Pediatric Oncology, Utrecht, The Netherlands.
Zitieren
APA
Wynn, R., Admiraal, R., & Lindemans, C. (2026). Serotherapy in transplant: Getting it right!. British Journal of Haematology, 208(5), 1885-1886. https://doi.org/10.1111/bjh.70456
Vancouver
Wynn R, Admiraal R, Lindemans C. Serotherapy in transplant: Getting it right!. British Journal of Haematology. 2026;208(5):1885-1886. doi:10.1111/bjh.70456
BibTeX
@article{Wynn2026,
author = {Wynn, Robert and Admiraal, Rick and Lindemans, Caroline},
title = {Serotherapy in transplant: Getting it right!},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {5},
pages = {1885--1886},
doi = {10.1111/bjh.70456}
}
EUVIMED